Skip to main content Skip to main navigation menu Skip to site footer

The immune response of SARS-CoV-2 vaccine in population with obesity: a systematic review

  • Nur Arafah ,
  • Gatot Soegiarto ,
  • Laksmi Wulandari ,


Link of Video Abstract:


Background: COVID-19 vaccines involve a humoral response to produce a neutralizing antibody that could protect subjects from severe COVID-19 infection. However, obesity tends to lower the immune response to the COVID-19 vaccine. Therefore, we conducted a systematic review to determine the immune response of various types of COVID-19 vaccines in a population with obesity.

Methods: We conducted a systematic review based on The Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) statement. Using keywords, we search studies from Taylor & Francis, PubMed, ScienceDirect, Cochrane, and EBSCOHost.

Results: We included eight cohort studies with 21,280 subjects after thorough selection and appraisal. Four studies stated that obesity was related to lower antibody titer post-SARS-CoV-2 vaccination, even though one study stated that obesity was not associated with long-term immune response. Another prospective cohort study involving approximately nine million populations stated that SARS-CoV-2 vaccination provided similar protection against COVID-19 compared to normoweight when underweight was a risk factor for lower protection. One study found that antibody titer wanes faster in obesity compared to normoweight. In addition, another study found lower antibody titer in obese men, whereas no significant findings were found in obese women.

Conclusion: Therefore, it should be noted that COVID-19 vaccination in an obese population tends to provide a lower immune response regardless of vaccine type and doses are given. This should inform clinicians who want to administer the COVID-19 vaccine to obese populations.


  1. Teijaro JR, Farber DL. COVID-19 vaccines: Modes of immune activation and future challenges. Nat Rev Immunol. 2021;21(4):195–197.
  2. Yao Y, Jeyanathan M, Haddadi S, Barra NG, Vaseghi-Shanjani M, Damjanovic D et al. Induction of autonomous memory alveolar macrophages requires T cell help and is critical to trained immunity. Cell. 2018;175(6):1634–1650.
  3. Soegiarto G, Wulandari L, Purnomosari D, Dhia FK, Ikhwan GH, Tri HS, et al. Hypertension is associated with antibody response and breakthrough infection in health care workers following vaccination with inactivated SARS-CoV-2. Vaccine. 2022;40(30):4046.
  4. Kabir A, Lotfi S, Farsi F, Pazouki A. Impact of body mass index on immunogenicity of hepatitis B vaccine in bariatric surgery candidates: a retrospective study. Diabetes Metab Syndr Clin Res Rev. 2021;15(5):102254
  5. Fan W, Chen XF, Shen C, Guo ZR, Dong C. Hepatitis B vaccine response in obesity: a meta-analysis. Vaccine. 2016;34(40):4835–4841
  6. Daryabor G, Kabelitz D, Kalantar K. An update on immune dysregulation in obesity-related insulin resistance. Scand J Immunol. 2019;89(4):e12747
  7. Mitsunaga T, Ohtaki Y, Seki Y, Yoshioka M, Mori H, Suzuka M, et al. The evaluation of factors affecting antibody response after administration of the BNT162b2 vaccine: a prospective study in Japan. PeerJ. 2021;9(1):e12316
  8. Faizo AA, Qashqari FS, El-Kafrawy SA, Barasheed O, Almashjary MN, Alfelali M, et al. A potential association between obesity and reduced effectiveness of COVID-19 vaccine-induced neutralizing humoral immunity. J Med Virol. 2023;95(1):e28130.
  9. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow C, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Systematic Revies. 2021;10(1):89.
  10. Munn Z, Moola S, Riitano D, Lisy K. The development of a critical appraisal tool for use in systematic reviews: addressing questions of prevalence. Int J Health Policy Manag. 2014;3(3):123–812.
  11. Alharbi JK, Al-Tawfiq JA, Alghnam S, Alwehaibe A, Alasmari A, Alsagaby SA, et al. Outcomes of single dose COVID-19 vaccines: eight month follow-up of a large cohort in Saudi Arabia. J Infect Public Health. 2022;15(5):573–577.
  12. Golec M, Fronczek M, Zembala-John J, Chrapiec M, Konka A, Wystyrk K, et al. Early and longitudinal humoral response to the SARS-CoV-2 mRNA BNT162b2 vaccine in healthcare workers: significance of BMI, adipose tissue, and muscle mass on long-lasting post-vaccinal immunity. Viruses. 2022;14(5):868.
  13. Herzberg J, Fischer B, Lindenkamp C, Becher H, Becker A, Honarpisheh H, et al. Persistence of immune response in health care workers after two doses BNT162b2 in a longitudinal observational study. Front Immunol. 2022;13(1):839922.
  14. Kara Z, Akcin R, Demir AN, Dinc HO, Taskin HE, Kocazeybek B, et al. Antibody response to SARS-CoV-2 vaccines in people with severe obesity. Obes Surg. 2022;32(9):2987–2993.
  15. Malavazos AE, Basilico S, Iacobellis G, Milani V, Cardani R, Boniardi F, et al. Antibody responses to BNT162b2 mRNA vaccine: infection naïve individuals with abdominal obesity warrant attention. Obesity (Silver Spring). 2022;30(3):606–613.
  16. Watanabe M, Balena A, Tuccinardi D, Tozzi R, Risi R, Masi D, et al. Central obesity, smoking habit, and hypertension are associated with lower antibody titres in response to COVID‐19 mRNA vaccine. Diabetes Metab Res Rev. 2022;38(1):e3465.
  17. Yamamoto S, Mizoue T, Tanaka A, Oshiro Y, Inamura N, Konishi M, et al. Sex-associated differences between BMI and SARS-CoV- 2 antibody titers following the BNT162b2 vaccine. Obesity (Silver Spring). 2022;30(5):999–1003.
  18. Gomez-Zorita S, Milton-Laskibar I, Garcia-Arellano L, Gonzalez M, Portillo MP. An overview of adipose tissue ACE2 modulation by diet and obesity – potential implications in COVID-19 infection and severity. Int J Mol Sci. 2021;22(15):7975.
  19. Moscogiuri G, Pugliese G, Laudisio D, Castellucci B, Barrea L, Savastano S, et al. The impact of obesity on immune response to infection: plausible mechanisms and outcomes. Obes Rev. 2021;22(6):e13216.
  20. Mauri C, Bosma A. Immune regulatory function of B cells. Annu Rev Immunol. 2012;30(1):221–241.
  21. Green WD, Beck MA. Obesity impairs the adaptive immune response to influenza virus. Ann Am Thorac Soc. 2017;14(5):406–409.
  22. Park HL, Shim SH, Lee EY, Cho W, Park S, Jeon HJ, et al. Obesity-induced chronic inflammation is associated with the reduced efficacy of influenza vaccine. Hum Vaccin Immunother. 2014;10(5):1181–1186.
  23. Liu F, Guo Z, Dong C. Influences of obesity on the immunogenicity of hepatitis B vaccine. Hum Vaccin Immunother. 2017;13(5):1014–1017.
  24. Stefan N. Metabolic disorders, COVID-19, and vaccine-breakthrough infections. Nat Rev Endocrinol. 2022;18(2):75–76.
  25. Kanneganti T, Dixit VD. Immunological complications of obesity. Nat Immunol. 2012;13(8):707–712.
  26. Levin EG, Lustig Y, Cohen C, Fluss R, Indenbaum V, Amit S, et al. Waning immune humoral response to BNT162b2 COVID-19 vaccine over 6 months. N Engl J Med. 2021;385(24):e84.
  27. Ko JY, Danielson ML, Town M, Derado G, Greenlund KJ, Kirley PD, et al. Risk factors for coronavirus disease 2019 (COVID-19) – associated hospitalization: COVID-19-associated hospitalization surveillance network and behavioral risk factor surveillance system. Clin Infect Dis. 2021;72(11):e695–703
  28. Ledford H. How obesity could create problems for a COVID vaccine. Nature. 2020;586(7830):488–489
  29. Sattar N, Valabhji J. Obesity as a risk factor for severe COVID-19: summary of the best evidence and implications for health care. Curr Obes Rep. 2021;10(3):282–289.
  30. Kompaniyets L, Goodman AB, Belay B. Body mass index and risk for COVID-19-related hospitalization, intensive care unit admission, invasive mechanical ventilation, and death – United States, March–December 2020. MMWR Morb Mortal wkly Rep. 2021;70(10):355–361.
  31. Pranata S, Vranada A, Armiyati Y, Samiasih A, Aisah S, Kurnia A, et al. Inflammatory markers for predicting severity, mortality, and need for intensive care treatments of a patient infected with covid-19: a scoping review. Bali Medical Journal. 2023;12(1):324–330.
  32. Wijaya T, Hsieh PP, Melinda F, Suarca IK. Hypercoagulation state in infant with COVID-19: a case report. Indonesia Journal of Biomedical Science. 2022;16(1):66–69.
  33. Butsch WS, Hajduk A, Cardel MI, Donahoo WT, Kyle TK, Standord FC et al. Obesity (Silver Spring). 2021;29(10):1575–1579
  34. Piernas C, Patone M, Astbury NM, Gao M, Sheikh Z, Khunti K et al. Associations of BMI with COVID-19 vaccine uptake, vaccine effectiveness, and risk of severe COVID-19 outcomes after vaccination in England: a population-based cohort study. Lancet Diabetes Endocrinol. 2022;10(8):571–580.
  35. Herawati S, Kandarini Y, Mulyantari NK, Prabawa IPY. Correlation of Neutrophil to Lymphocyte Ratio with Interleukin-10 in Diagnosis and Monitoring of Coronavirus Disease-19 Patients. Open Access Macedonian Journal of Medical Sciences. 2022;10(B):63-66.

How to Cite

Arafah, N., Soegiarto, G., & Wulandari, L. (2023). The immune response of SARS-CoV-2 vaccine in population with obesity: a systematic review. Bali Medical Journal, 12(2), 1522–1527.




Search Panel